(Q33944781)

30 July 2017

1 reference

title

Molecular targets for breast cancer therapy and prevention (English)

1 reference

30 July 2017

1 reference

Bange J

1

1 reference

30 July 2017

Zwick E

series ordinal

2

1 reference

30 July 2017

Ullrich A

series ordinal

3

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

30 July 2017

1 reference

30 July 2017

volume

7

1 reference

30 July 2017

issue

5

1 reference

30 July 2017

page(s)

548-552

1 reference

ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics

30 July 2017

cites work

1 reference

7 January 2021

Cancer statistics, 2000.

1 reference

7 January 2021

Annual hazard rates of recurrence for breast cancer after primary therapy.

1 reference

7 January 2021

Single and combination nonhormonal chemotherapy in breast cancer

1 reference

7 January 2021

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women

1 reference

7 January 2021

p53-independent apoptosis induced by paclitaxel through an indirect mechanism

1 reference

7 January 2021

High constant incidence in twins and other relatives of women with breast cancer.

1 reference

7 January 2021

Adjuvant therapy for breast cancer

1 reference

7 January 2021

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

1 reference

7 January 2021

Molecular mechanisms underlying ErbB2/HER2 action in breast cancer

1 reference

7 January 2021

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

1 reference

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

7 January 2021

Clinical trials of Herceptin(trastuzumab).

1 reference

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

7 January 2021

Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway

1 reference

7 January 2021

Inhibition of CDKs as a therapeutic modality.

1 reference

7 January 2021

Preclinical and clinical development of cyclin-dependent kinase modulators

1 reference

7 January 2021

Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor

1 reference

7 January 2021

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

1 reference

7 January 2021

Mutations truncating the EP300 acetylase in human cancers

1 reference

7 January 2021

The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis

1 reference

7 January 2021

The mammary gland iodide transporter is expressed during lactation and in breast cancer

1 reference

7 January 2021

Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis.

1 reference

7 January 2021

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

1 reference

7 January 2021

Tumor angiogenesis: past, present and the near future

1 reference

7 January 2021

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

1 reference

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

7 January 2021

Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer

1 reference

7 January 2021

Breast cancer chemoprevention

1 reference

7 January 2021

Fenretinide and cancer prevention

1 reference

7 January 2021

Role of retinoid receptors in the prevention and treatment of breast cancer

1 reference

7 January 2021

Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo

1 reference

7 January 2021

Combinatorial chemoprevention of intestinal neoplasia

1 reference

7 January 2021

Regulation of cyclooxygenase-2 pathway by HER2 receptor

1 reference

7 January 2021

Molecular portraits of human breast tumours

1 reference

7 January 2021

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

7 January 2021

Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer

1 reference

7 January 2021

Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers

1 reference

7 January 2021

Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy

1 reference

7 January 2021

Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment

1 reference

7 January 2021

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.

1 reference

7 January 2021

Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy.

1 reference

7 January 2021

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

1 reference

7 January 2021

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer

1 reference

7 January 2021

Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer

1 reference

7 January 2021

No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer

1 reference

7 January 2021

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

7 January 2021

Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer

1 reference

7 January 2021

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1 reference

7 January 2021

Identifiers

DOI

10.1038/87872

1 reference

30 July 2017

1 reference